Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $2.7 million
Deal Type : Funding
New Alliance to Develop Sublingual Oxytocin to Prevent Postpartum Hemorrhage
Details : The proceeds will be used for the launch of a Phase II Clinical Trial to determine the optimal dose of an innovative sublingual oxytocin treatment designed to prevent postpartum hemorrhage.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
November 21, 2024
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $2.7 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?